A Multicenter Phase 1 Dose Escalation Study of SN2310 [TOCOSOL camptothecin] Injectable Emulsion in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs SN 2310 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors OncoGenex Pharmaceuticals
- 09 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 09 Jun 2009 Status changed from active, no longer recruiting to completed, as reported by OncoGenex media release.
- 05 Nov 2008 Sponsor and affiliate changed from Sonus Pharmaceuticals to OncoGenex Pharmaceuticals, based on information from ClinicalTrials.gov.